GlassScriptPhysician profile
Seida Velija
NPI 1871987198
$62,352.53
in general payments reported to CMS, 2019-2025
27 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,655 · 2022: $2,109 · 2023: $2,189 · 2024: $9,951 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $11K · Food and Beverage: $10K · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,798.00 |
| Travel and Lodging | $11,141.97 |
| Food and Beverage | $10,498.76 |
| Education | $149.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26,340.41 | 2021-2025 | Entyvio, Actos, Eohilia |
| Lilly USA, LLC | $25,316.40 | 2023-2025 | Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,022.06 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,460.78 | 2021-2025 | |
| Janssen Biotech, INC. | $1,317.93 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $851.90 | 2021-2025 | Livdelzi, Vemlidy |
| Ardelyx, INC. | $746.74 | 2022-2025 | Ibsrela |
| Celgene Corporation | $727.81 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $686.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $578.45 | 2021-2025 | Ocaliva |
| Pfizer INC. | $479.85 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $464.65 | 2021-2025 | Linzess |
| Merck Sharp & Dohme LLC | $261.21 | 2021-2024 | Dificid |
| Qol Medical, LLC | $237.47 | 2021-2024 | Sucraid, Sucraid |
| Intra-Sana Laboratories | $150.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $149.72 | 2024-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $134.44 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $127.46 | 2021-2023 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $64.46 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $45.10 | 2025 | Iqirvo |
| Exact Sciences Corporation | $44.46 | 2025 | The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $41.46 | 2023 | |
| Genzyme Corporation | $39.95 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $22.80 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $13.43 | 2021 | |
| Biodelivery Sciences International, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seida Velija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.